Opinion|Videos|March 10, 2026
Exploring HER2 and Biomarker Recognition in Gastroesophageal Adenocarcinoma
Author(s)Matthew Arango, PharmD
Matthew Arango, PharmD, discusses the importance and challenges of HER2 testing in gastroesophageal adenocarcinoma and how biomarker results influence early treatment decisions and patient counseling.
Episodes in this series
This program was supported by Jazz Pharmaceuticals, content independence maintained by Pharmacy Times.
In this portion of the conversation, Matthew Arango, PharmD, delves into the critical role of HER2 testing in guiding therapy for gastroesophageal adenocarcinoma (GEA). He explains how understanding a patient’s disease trajectory shapes medication selection and counseling from the very start. Arango also highlights why HER2 assessment in GEA poses unique challenges compared with other malignancies and how delays or gaps in biomarker data can complicate timely, appropriate treatment planning.
Related Content
Latest CME
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
4
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
5